Reformation of oxygen gradient in a disturbed sediment. by Xuegang Mao (599968)

Subjects:

Decreased Aβ oligomer immunoreactivity in APPxPS1 mice after treatment with hNGFP61S/R100E: polyclonal pAb A11 antibody. by Simona Capsoni (161132)

DHEA decreases the apoptotic loss of TrkA positive sensory neurons in dorsal root ganglia of NGF null mouse embryos. by Iakovos Lazaridis (223341)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Increasing temperature decreases oxygen concentration and decreasing oxygen content decreases neuronal excitability. by Yuguo Yu (172221)

“…Increasing temperature can dramatically decrease oxygen levels. B. Response of layer 2/3 pyramidal cells (n = 5) to the intracellular injection of a depolarizing current pulse (200 pA, 500 ms) at different temperatures (same experiments as in A). …”

Expression of a 65kDa isoform of eIF2Bε leads to a global decrease in protein synthesis. by Lauren K. Brady (4479244)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Supplementary Material for: Kidney and cardiovascular outcomes in older population with mildly to moderately decreased kidney function - A nationwide cohort study by Jeon J. (10323467)

“…Mildly to moderately decreased eGFR was associated with a higher risk of kidney failure, CVD, and all-cause death compared with eGFR 60–89 ml/min/1.73 m2 in the old and very old groups, regardless of proteinuria (adjusted hazard ratio [95% confidence interval] in the very old group without proteinuria: kidney failure 3.048 [2.495–3.722], CVD 1.103 [1.066–1.142], and all-cause death 1.172 [1.144–1.201]). …”

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

RhoE gt/gt mice show a delay in neuromuscular junction maturation and a decrease in the number of spinal motoneurons. by Enric Mocholí (223047)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects: